Definitive Contract 75N93024C00023
Award Date
9/30/24
Potential Completion Date
9/29/29
Potential Value
$9.8M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
University Of Chicago
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Chicago, IL 60637, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
13
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $9,983,467.70 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Chicago to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. The contract has a period of performance through April 30, 2026 and was originally solicited through a Broad Agency Announcement issued by NIAID in 2018. The University of Chicago is collaborating with the IIT Research Institute and the University of...
This federal contract award to the University of Chicago, valued at $7,281,050.38, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) for the development of influenza vaccines using an immuno-modulator adjuvant and a multi-platform approach. The contract is a Definitive Contract with a Firm Fixed Price pricing type and has a completion date of September 29, 2028. The University of Chicago, a prestigious private research university, has been awarded this contract to...
The Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,896,692 Vaccine Adjuvant Discovery Program (VADP) contract to the University of Montana. The 5-year contract, which has no set-aside designation, aims to identify, characterize, and advance novel synthetic adjuvants for use in combination with bacterial and fungal antigens to induce a safe and durable T-helper 17 (Th17) and/or Th17/Th1 immune response. The University of Montana...
This is a $61,272,508.00 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Chicago for research and development activities. The contract does not have a set-aside designation, indicating the University of Chicago was selected as a prime contractor for this effort based on its extensive expertise and capabilities in this domain. The contract supports the evaluation and development of animal and animal replacement models for...
This federal contract award, valued at $10,517,896.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of California, San Diego (UCSD). The award is part of NIAID's Vaccine Adjuvant Discovery Program (VADP), which supports the identification and characterization of novel, effective, and safe vaccine adjuvants. The contract does not have a set-aside designation. UCSD will lead the research efforts, which will focus on four key areas: (1)...
This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...
This is a $10,725,896 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Oregon Health & Science University (OHSU). The contract is for the Vaccine Adjuvant Discovery Program, which aims to identify novel adjuvant candidates that can enhance the efficacy of human vaccines. The contract is a definitive, cost-no-fee contract with a performance period ending on March 31, 2026. No set-aside was...
This federal contract award is for a research program to compare multiple vaccine adjuvants using various vaccine and antigen platforms. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a $6,757,725 definitive contract to Duke University, a private research institution, to conduct comprehensive immune assessments of adjuvant strength, quality, breadth, and durability of responses. The research will employ "omics"...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...
This federal contract award, valued at $9,189,961.00, was granted to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a for-profit limited liability company based in Switzerland. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, for the Vaccine Adjuvant Discovery Program. This five-year definitive contract, running from September 2024...